Organon & Co. Form 8-K Summary
Business Context and Reporting Period
Organon & Co. filed a Form 8-K dated June 6, 2023, reporting the results of its 2023 annual meeting of shareholders. The filing was signed on June 8, 2023. It contains no quarterly or annual financial statements.
- Shares entitled to vote: 255,061,586
- Shares present in person or by proxy: 216,548,315, or approximately 85% of entitled shares
- Common stock trading symbol: OGN; exchange: NYSE
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Meeting Results and Material Changes
- Director elections: All four Class II nominees were elected to serve until the 2025 annual meeting or until their successors are elected and qualified.
- Carrie S. Cox: 161,582,913 for; 21,364,441 withheld; 307,563 abstentions; 33,293,398 broker non-votes.
- Alan Ezekowitz, M.D.: 181,298,050 for; 1,681,234 withheld; 275,633 abstentions; 33,293,398 broker non-votes.
- Helene Gayle, M.D.: 180,024,350 for; 2,950,230 withheld; 280,337 abstentions; 33,293,398 broker non-votes.
- Deborah Leone: 181,439,869 for; 1,544,341 withheld; 270,707 abstentions; 33,293,398 broker non-votes.
- Executive compensation: Shareholders approved, on a non-binding advisory basis, the compensation of the named executive officers: 170,522,652 for; 11,916,370 against; 815,895 abstentions; 32,293,398 broker non-votes.
- Independent auditor: Shareholders ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2023: 215,254,031 for; 840,020 against; 454,264 abstentions; no broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, business outlook, risk updates, contingencies, or unusual financial items. It explains that broker non-votes occur when nominees lack discretionary voting authority and have not received voting instructions from beneficial owners; broker non-votes count toward quorum but generally do not represent votes on the relevant proposal.
Important Facts to Verify
- Confirm the elected Class II directors’ terms and any subsequent changes to board composition.
- Review the proxy statement for the detailed executive compensation disclosures and advisory vote context.
- Verify the reported broker non-vote count for the executive compensation proposal against the meeting vote tabulation; the filing reports 32,293,398 for that proposal versus 33,293,398 for each director election.
- For financial performance, debt, liquidity, and outlook, consult Organon’s applicable quarterly or annual filings because this Form 8-K contains no such information.